Valuation : Oncopeptides AB

Market Cap 704M 73.55M 63.29M 59.54M 54.39M 102M 6.94B 102M 273M 3.56B 276M 270M 11.48B P/E 2026 *
-3.87x
P/E 2027 * -7.57x
Enterprise Value 770M 80.44M 69.22M 65.13M 59.5M 111M 7.6B 112M 299M 3.9B 302M 295M 12.55B EV / Sales 2026 *
6.31x
EV / Sales 2027 * 3.23x
Free-Float
96.1%
Yield 2026 *
-
Yield 2027 * -
1 day-5.77%
1 week-12.23%
Current month-6.81%
1 month+11.39%
3 months+6.21%
6 months+12.37%
Current year-62.96%
1 week 1.77
Extreme 1.767
2.02
1 month 1.55
Extreme 1.551
2.16
Current year 1.26
Extreme 1.255
4.91
1 year 1.26
Extreme 1.255
6.55
3 years 1.1
Extreme 1.1
10.2
5 years 1.1
Extreme 1.1
53.4
10 years 1.1
Extreme 1.1
215
Manager TitleAgeSince
Chief Executive Officer 46 2023-08-06
Director of Finance/CFO 52 2023-11-12
Chief Tech/Sci/R&D Officer 54 2023-08-31
Director TitleAgeSince
Director/Board Member 65 2011-12-31
Director/Board Member 63 2017-01-31
Chairman 78 2018-05-16
Date Insider Type Main position Quantity % Market Cap. Importance
3/20/26 Free

Chief Technology Officer

3,000 0.0008%
3/18/26 Buy 14,631 0.0038%
3/17/26 Free

Investor Relations Manager

66 0.0000%
Change 5-day change 1-year change 3-year change Capi.($)
-5.77%-12.23%-62.88%-77.53% 73.55M
-1.79%-2.27%+43.23%+88.96% 67.98B
-2.06%-0.18%+39.67%+86.44% 64.94B
-0.31%+6.54%-12.96%+378.92% 27.58B
+0.86%+1.65%-7.74%-14.95% 26.06B
-3.00%-2.90%+33.13%+12.54% 25.74B
-1.46%+0.42%+23.61%-18.61% 20.09B
-2.96%-15.21%+216.20%+368.10% 17.16B
-1.49%-4.88%-6.60%+531.89% 14.92B
-0.20%+8.37%+55.78%+164.98% 14.62B
Average -1.82%-0.99%+32.14%+152.07% 27.92B
Weighted average by Cap. -1.52%+0.17%+38.35%+137.29%

Financials

2026 *2027 *
Net sales 122M 12.75M 10.97M 10.32M 9.43M 17.64M 1.2B 17.69M 47.34M 618M 47.89M 46.84M 1.99B 240M 25.06M 21.57M 20.29M 18.54M 34.67M 2.37B 34.77M 93.04M 1.21B 94.11M 92.06M 3.91B
Net income -180M -18.81M -16.19M -15.23M -13.92M -26.03M -1.78B -26.1M -69.85M -911M -70.65M -69.11M -2.94B -78M -8.15M -7.02M -6.6M -6.03M -11.28M -770M -11.31M -30.27M -395M -30.62M -29.95M -1.27B
Net Debt 66M 6.9M 5.94M 5.59M 5.1M 9.54M 651M 9.57M 25.61M 334M 25.91M 25.34M 1.08B 70.5M 7.37M 6.34M 5.97M 5.45M 10.2M 696M 10.22M 27.36M 357M 27.67M 27.07M 1.15B
Logo Oncopeptides AB
Oncopeptides AB is a Sweden-based biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The Company’s lead product candidate PEPAXTO (melphalan flufenamide, also known as melflufen) has been approved in relapsed or refractory multiple myeloma by The U.S. Food and Drug Administration. Melphalan flufenamide is the first drug originated from the Company PDC-platform and is evaluated in a clinical study program, including the ongoing phase 3 OCEAN study. Melphalan flufenamide is an anticancer peptide-drug conjugate for patients with relapsed or refractory multiple myeloma. The drug uses technology that links a peptide carrier to a cytotoxic agent, resulting in a lipophilic compound. Due to its high lipophilicity, it is distributed into the cells. Melphalan flufenamide is designed to leverage aminopeptidases, enzymes which are overexpressed in myeloma cells and cause the release of the cytotoxic agents in the cells.
Employees
69
Date Price Change Volume
26-09-04 SEK 1.780 -5.77% 3,624,326
26-09-03 SEK 1.889 -0.32% 2,702,423
26-09-02 SEK 1.895 +1.34% 1,384,536
26-09-01 SEK 1.870 -2.09% 2,189,356
26-08-31 SEK 1.910 -5.82% 4,132,557
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
1.780SEK
Average target price
2.467SEK
Spread / Average Target
+38.58%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ONCO Stock